320 related articles for article (PubMed ID: 23773743)
1. [Orbital myositis associated with ipilimumab].
Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
Papavasileiou E; Prasad S; Freitag SK; Sobrin L; Lobo AM
Ocul Immunol Inflamm; 2016; 24(2):140-6. PubMed ID: 25760920
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression.
Borodic GE; Hinkle D
Ophthalmic Plast Reconstr Surg; 2014; 30(1):83. PubMed ID: 24398505
[No Abstract] [Full Text] [Related]
4. A case report of orbital inflammatory syndrome secondary to ipilimumab.
Henderson AD; Thomas DA
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e68-70. PubMed ID: 24814274
[TBL] [Abstract][Full Text] [Related]
5. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
6. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
8. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
12. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
13. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
du Rusquec P; Saint-Jean M; Brocard A; Peuvrel L; Khammari A; Quéreux G; Dréno B
J Immunother; 2014; 37(6):348-50. PubMed ID: 24911795
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
Bhatia S; Huber BR; Upton MP; Thompson JA
J Immunother; 2009; 32(2):203-5. PubMed ID: 19238020
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Savoia P; Astrua C; Fava P
Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
20. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]